NEOGEN Corp. recorded a net loss of $11.3 million for Q4, with revenue slightly down at $225.3 million. The company's focus on core food safety growth suggests potential for recovery and future profitability.
Key Highlights
- NEOGEN's Q4 revenue totaled $225.3 million, showing a minimal decline of 0.1% year-over-year.
- The company reported an adjusted net income of $18.7 million, translating to earnings per share of $0.09.
- Year-to-date, NEOG shares have surged by 64.7%, reaching a market capitalization of approximately $2.5 billion.
- NEOGEN anticipates strong core growth in FY 2027, driven by enhanced operational efficiency and market initiatives.
NEOGEN Corp. (NASDAQ: NEOG) reported a net loss of $11.3 million in its fiscal fourth quarter ending June 30, marking a significant contrast to the previous year’s quarter when losses were substantially higher. The company’s revenue remained relatively stable at $225.3 million, a slight decrease of 0.1% year-over-year but accompanied by core revenue growth of 4.3%, the highest growth rate since the fiscal year 2023. This performance deviates somewhat from market expectations, as the consensus estimate for earnings per share (EPS) was pegged at $-0.07, with NEOG delivering a slightly better result at $-0.05.
Steady Revenue Amid Diverse Performance
The company's revenue breakdown illustrates a notable performance in its Food Safety segment, which yielded a growth of 3.1%. Core revenue growth in this area soared to 5.8%, fueled by strong demand for its indicator testing and culture media products, up 9.5%. Conversely, the Animal Safety segment faced challenges, revealing an 8.2% decline in revenue against the same period last year; nevertheless, core growth in this domain increased slightly by 0.5%.
NEOGEN’s diverse revenue streams underscore its resilience, despite some headwinds in specific areas. The company’s overall revenue for the fiscal year reached $870.4 million, reflecting a 2.7% decrease compared to the prior year but still indicating steady operational focus.
Positive Cash Flow Signals Strength
In Q4, NEOGEN generated $30.2 million in cash flow from operations and reported free cash flow of $26.2 million, demonstrating the effectiveness of its cost-saving initiatives. The adjusted EBITDA for the quarter was $45.4 million, resulting in an impressive adjusted EBITDA margin of 20.2%. This marks significant improvement over the prior year's same period where losses were chronicled across various financial metrics.
Improved gross margin figures, rising to 47.8%, highlight operational efficiency amidst pricing adjustments and product mix enhancements. Shareholders may find confidence in these cash flow metrics, as they signify a capable response to prior financial difficulties.
Market Performance and Future Outlook
With a market capitalization of about $2.5 billion and a 52-week trading range of $4.56 to $11.56, NEOGEN is positioning itself for a stronger foothold in the food safety market. The company's emphasis on disciplined execution, coupled with plans to enhance operational efficiency through technology and innovative product offerings, is aimed at bolstering future profitability. This proactive strategy will be important as NEOGEN prepares for upcoming fiscal year 2027 guidance, projected to include significant growth initiatives and increased market penetration.
Anticipated Catalysts Ahead
Investors should keep an eye on key developments in the upcoming quarters, particularly the anticipated unveiling of NEOGEN’s new manufacturing processes for its Petrifilm® product line, set to commence in November 2026. As the company refines its product offerings and capitalizes on enhanced market strategies, it could provide added momentum toward achieving targeted revenue growth and operational efficiency. The planned sale of its genomics business to Zoetis Inc. expected to conclude in 2027, may also yield significant capital for debt reduction, further optimizing the company’s financial standing.
Analysis based on the Form 8-K filed 30 July 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...